Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $10B; returns 1 day -4.2%, 1 week -3.4%, 1 year +2.4%.

Madrigal Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), a severe liver disease.

Groups MDGL belongs to

• Biopharmaceutical
• Pharmaceuticals
• Commercial Stage Biotech
• Liver Disease
• NASH
• Metabolic Disorders
• Healthcare
• Biotechnology
• Commercial Stage
• Fibrosis

MDGL financial model: income statement, cash flow and balance sheet